Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80μg Estradiol/4mg Progesterone and 160μg Estradiol/8mg Progesterone Intravaginal Rings) in Healthy PostMenopausal Women

Trial Profile

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80μg Estradiol/4mg Progesterone and 160μg Estradiol/8mg Progesterone Intravaginal Rings) in Healthy PostMenopausal Women

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol/progestogen (Primary) ; Estradiol; Progestogen
  • Indications Genitourinary disorders; Menopausal syndrome; Vasomotor symptoms
  • Focus Pharmacokinetics
  • Sponsors Dare Bioscience
  • Most Recent Events

    • 26 Jan 2023 According to a Dare Bioscience media release, data published in the journal Menopause, which is the journal of the North American Menopause Society.
    • 06 Dec 2022 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2021 According to a Dar Bioscience media release, data will be presented at the European Menopause and Andropause Society (EMAS) 13th European Congress on Menopause and Andropause.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top